Market Overview

UPDATE: Stifel Nicolaus Initiates Align Technology at Buy on EPS Reacceleration

Related ALGN
5 Health Care Stocks Hurting From The Affordable Care Act
Align Technology Surges 5% Amid Credit Suisse Upgrade

Stifel Nicolaus initiated coverage on Align Technology (NASDAQ: ALGN) with a Buy rating and a $32 price target.

Stifel Nicolaus commented, "Admittedly, EPS growth is likely to be suppressed in 1H13 due to difficult comps and near-term spend (purchase of APAC distributor). However, we expect a quick payoff on the investments and point to our estimated 2H13 y/y EPS growth of 40%. Once investors get comfortable that EPS is poised to meaningfully accelerate, multiple expansion will quickly follow. Despite the 3Q12 earnings disappointment, we believe Align's fundamentals remain intact. Specifically, our doctor diligence points to the potential for 2013 case volume upside, competition continues to flounder and Align's cash flow remains strong (YE net cash per share of $6)."

Align Technology closed at $26.03 on Wednesday.

Latest Ratings for ALGN

DateFirmActionFromTo
Oct 2014Goldman SachsUpgradesNeutralBuy
Oct 2014Credit SuisseUpgradesNeutralOutperform
Jul 2014JefferiesMaintainsHold

View More Analyst Ratings for ALGN
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (ALGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional